Cytokinetics (CYTK) said Monday it has dosed the first participants in a phase 1 clinical study of CK-4015089 as a potential treatment for a specific type of muscular dystrophy and other impaired muscle conditions.

The randomized, double-blind, placebo-controlled study consists of single-dose and multiple-dose ascending cohorts of 10 participants each, said the company

The drug, also called CK-089, increased muscle force and function in animal testing, the company said.

Shares of the company were up 2% in recent Monday premarket activity.

Price: 57.00, Change: +1.16, Percent Change: +2.08